Gastric Cancer Therapy Market - Growth, Trends, and Forecast (2019 - 2024)

The Gastric Cancer Therapy Market is segmented by Therapy Type, End User (Hospitals and Specialty Clinics, Cancer Research and Treatment Centers, and Ambulatory Surgery Centers), and Geography.

Market Snapshot

Picture17
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

15.3%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world. The high mortality rates are primarily caused by the late diagnosis of the disease, with patients often missing the opportunity for a surgical cure, and cancer already having been developed into an advanced stage when identified. Gastric cancer is a common cancer, found, especially in the developing economies of Eastern Asia, Middle and Eastern Europe, and South America. Cases of gastric cancer in China account for 44.2% of the new gastric cancer cases, globally.  According to the estimates of GLOBOCAN 2018, the number of incident cases of stomach cancer in Asia in 2018 was about 769,728, and it is expected to increase to 947,186, by 2025. According to the estimates of GLOBOCAN, in 2018, South Korea had the highest rate of stomach cancer, followed by Mongolia. Additionally, in men the stomach cancer rate in South Korea was 57.8, while in women, it was about 23.5, in 2018. Although chemotherapy can improve chances of survival for patients with advanced gastric cancer, the overall survival rate is still very low. A significant number of studies have shown that molecular targeted therapy can further improve the survival rates of patients suffering from gastric cancer. Recently, chemotherapeutic agents, such as pembrolizumab and ramucirumab, have been used for the treatment of gastric cancer. Due to the increasing number of molecular studies of gastric cancers, new molecular targeted drugs have entered into clinical use. For example, Trastuzumab, an antibody targeting the human epidermal growth factor receptor 2 (HER2), can significantly improve the survival rates of advanced gastric cancer patients. Thus, the rising incidences of the stomach cancer is one of the major factors driving the growth of the market.

Scope of the Report

Gastric cancer is also known as stomach cancer, and it is characterized by the growth of cancerous cells within the lining of the stomach. Stomach cancer is a relatively rare type of cancer. Some of the risk factors associated with stomach cancer are lymphoma, H. pylori bacterial infections, tumors in other parts of the digestive system, and stomach polyps.

Therapy Type
Surgery
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
End User
Hospitals and Specialty Clinics
Cancer Research and Treatment Centers
Ambulatory Surgery Centers
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy Segment is Expected to Register High CAGR during the Forecast Period

Chemotherapy is the most common form of therapeutics used to stop or slow the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain area, while chemotherapy works throughout the whole body. This means that chemotherapy can kill and damage cancer cells that have spread to other parts of the body, far away from the original tumor. Even though chemotherapy has many associated side effects, it is still the therapy of choice among most oncologists, worldwide. It is also cheap, when compared to immunotherapies, and is administered either through an intravenous route or orally.  Some of the chemotherapy drugs used in the treatment of stomach cancer are 5-FU, Capecitabine, Carboplatin, Cisplatin, Docetaxel, Epirubicin, Irinotecan, Oxaliplatin, and Paclitaxel. Stomach cancer prevalence is expected to increase in the coming years, and the rising number of cancer cases is driving the chemotherapy segment, which is expected to grow further during the forecast period. Chemotherapy-based drugs have been the choice of treatment for decades, and have been the among the major treatment options for the treatment of several types of cancers. Hence, the market is expected to witness substantial growth during the forecast period.

Gastric Cancer Therapy Market - Image 3

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do the Same during the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In the North American region, the United States holds the largest market share. This is attributed to the rising prevalence of stomach cancer and the availability of advanced technology in cancer research and treatment centers. The region is well-developed, in terms of availability of advanced technologies to treat the cancers, and medical device companies are pushing themselves to compete with the established players across the United States and Canada. Such factors boost the growth of the market in North America.

Picture19

To understand geography trends, Download Sample Report

Competitive Landscape

The gastric cancer therapy market is competitive and consists of a few major players. In terms of share, a few of the major players are currently dominating the market. Some of the major players in the market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Pfizer, Merck & Co. Inc., and Celltrion Inc., among others.

Major Players

  1. F. Hoffmann-La Roche Ltd
  2. Bristol-Myers Squibb
  3. Pfizer Inc.
  4. Merck & Co. Inc.
  5. Celltrion Inc.

* Complete list of players covered available in the table of contents below

Picture21

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Gastric Cancer

      2. 4.2.2 Introduction of Novel Therapies for Metastatic Stomach Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Cancer Therapy and Side Effects of Cancer Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Therapy Type

      1. 5.1.1 Surgery

      2. 5.1.2 Chemotherapy

      3. 5.1.3 Targeted Therapy

      4. 5.1.4 Immunotherapy

      5. 5.1.5 Radiation Therapy

    2. 5.2 End User

      1. 5.2.1 Hospitals and Specialty Clinics

      2. 5.2.2 Cancer Research and Treatment Centers

      3. 5.2.3 Ambulatory Surgery Centers

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb

      2. 6.1.2 Celltrion Inc.

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Imugene Limited

      7. 6.1.7 Novartis AG

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Otsuka Holdings Co. Ltd

      10. 6.1.10 Pfizer Inc.

      11. 6.1.11 Sanofi

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products, Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information